{"ATC Code":"N - Nervous system","Abbreviation":"","Aliases":["Insumin","Flurazepamum","Dalmane-R","Dalmane","Ro-5-6901/3","IHP475989U","7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one","7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one","7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one","Stauroderm"],"Biological Half-Life":"The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours","CAS":"17617-23-1","ChEBI":"CHEBI:5128","ChEMBL":"CHEMBL968","Chirality":"achiral","Color/Form":"White rods from ether-petroleum ether","DEA no":2767,"Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Benzodiazepines; Hypnotics and Sedatives","Drug Indication":"For short-term and intermittent use in patients with recurring insomnia and poor sleeping habits","Drug Warnings":"THE EFFICACY OF DRUG BEYOND 22 CONSECUTIVE NIGHTS OF USE IS NOT KNOWN. IN ONE STUDY, PATIENTS RATED FLURAZEPAM MORE HIGHLY THAN SECOBARBITAL ... . FLURAZEPAM SHOULD BE USED CAUTIOUSLY WHEN HEPATIC OR RENAL FUNCTION IS IMPAIRED. /FLURAZEPAM DIHYDROCHLORIDE/","DrugClasses":[],"EINECS":"241-591-7","European Community (EC) Number":"241-591-7","FDA Pharmacological Classification":"IHP475989U","Human Drugs":"Breast Feeding; Lactation; Milk, Human; Benzodiazepines; Hypnotics and Sedatives","IUPACName":"7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one","InChI":"InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3","InChIKey":"SAADBVWGJQAEFS-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)","Melting Point":"190-220","MolecularFormula":"C\u003csub\u003e21\u003c/sub\u003eH\u003csub\u003e23\u003c/sub\u003eClFN\u003csub\u003e3\u003c/sub\u003eO","MolecularWeight":"387.9 g/mol","Pharmacodynamics":"Flurazepam, a benzodiazepine derivative, is a hypnotic agent which does not appear to decrease dream time as measured by rapid eye movements (REM). Furthermore, it decreases sleep latency and number of awakenings for a consequent increase in total sleep time.","Physical Description":"Solid","PubChemId":3393,"Record Description":["Flurazepam is a 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia. It has a role as a sedative, an anticonvulsant, a GABAA receptor agonist and an anxiolytic drug. It is a 1,4-benzodiazepinone, an organochlorine compound, a member of monofluorobenzenes and a tertiary amino compound.","Flurazepam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","A benzodiazepine derivative used mainly as a hypnotic.","Flurazepam is a Benzodiazepine.","Flurazepam is an orally available benzodiazepine used for therapy of insomnia. As with most benzodiazepines, flurazepam has not been associated with serum aminotransferase or alkaline phosphatase elevations during therapy, and clinically apparent liver injury from flurazepam has been reported, but is rare.","Flurazepam is a member of the benzodiazepines and a long-acting depressor of the central nervous system (CNS) with sedative and hypnotic effects. Flurazepam binds to a specific site on the benzodiazepine-gamma-aminobutyric acid (GABA)-A-chloride ionophore receptor complex located on the neuronal membrane. Binding causes an allosteric modification of the receptor thereby enhancing the affinity of GABA to the receptor leading to an increase in the frequency of chloride-channel opening events, which leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential, and a decrease in neuronal excitability. By modulating binding of the GABA inhibitory neurotransmitter to GABA-A receptors in the ascending reticular activating system, flurazepam blocks arousal of the cortical and limbic system, thereby exerting its sedative and hypnotic effect.","FLURAZEPAM is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and is indicated for insomnia and has 5 investigational indications. This drug has a black box warning from the FDA.","Flurazepam is only found in individuals that have used or taken this drug. It is a benzodiazepine derivative used mainly as a hypnotic. [PubChem]Flurazepam binds to an allosteric site on GABA-A receptors. Binding potentiates the action of GABA on GABA-A receptors by opening the chloride channel within the receptor, causing chloride influx and hyperpolarization.","A benzodiazepine derivative used mainly as a hypnotic.","See also: Flurazepam Hydrochloride (has salt form); Flurazepam Monohydrochloride (has salt form).","Flurazepam is a 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia. It has a role as a sedative, an anticonvulsant, a GABAA receptor agonist and an anxiolytic drug. It is a 1,4-benzodiazepinone, an organochlorine compound, a member of monofluorobenzenes and a tertiary amino compound.","LiverTox|CNS|Sedative/Hypnotic|Benzodiazepine"],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Flurazepam"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q418998"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB00690"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/3393"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.3276.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL968"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5128"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=17617-23-1"},{"name":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0014828"},{"name":"KEGG","url":"https://www.kegg.jp/entry/D00329"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/IHP475989U"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID1023071"}],"SMILES":"CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F","Solubility":"OFF-WHITE TO YELLOW, CRYSTALLINE POWDER; SLIGHT ODOR TO ODORLESS; MODERATELY HYGROSCOPIC; MELTS WITH DECOMPOSITION AT ABOUT 212 °C; SOLUBILITY: 1 G IN 2 ML WATER; FREELY SOL IN ALCOHOL; SLIGHTLY SOL IN CHLOROFORM /FLURAZEPAM DIHYDROCHLORIDE/","Stability/Shelf Life":"Store in air tight containers. Protect from light. /Flurazepam hydrochloride/","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="146.242mm" version="1.2" viewBox="0 0 84.043 146.242" width="84.043mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="147.0" stroke="none" width="85.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="69.057" x2="72.442" y1=".979" y2="15.838"/>
                  
            <line class="bond" id="mol1bnd2" x1="72.442" x2="64.234" y1="15.838" y2="23.448"/>
                  
            <line class="bond" id="mol1bnd3" x1="57.988" x2="46.705" y1="25.187" y2="21.702"/>
                  
            <line class="bond" id="mol1bnd4" x1="46.705" x2="43.32" y1="21.702" y2="6.843"/>
                  
            <line class="bond" id="mol1bnd5" x1="62.136" x2="64.652" y1="30.015" y2="41.059"/>
                  
            <line class="bond" id="mol1bnd6" x1="64.652" x2="53.476" y1="41.059" y2="51.42"/>
                  
            <line class="bond" id="mol1bnd7" x1="53.476" x2="55.993" y1="51.42" y2="62.465"/>
                  
            <line class="bond" id="mol1bnd8" x1="60.166" x2="71.695" y1="67.049" y2="69.734"/>
                  
            <g class="bond" id="mol1bnd9">
                        
                <line x1="70.379" x2="77.799" y1="69.428" y2="60.165"/>
                        
                <line x1="72.282" x2="79.702" y1="70.952" y2="61.69"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="77.799" x2="74.089" y1="60.165" y2="64.7965"/>
                <line class="hi" stroke="#FF0D0D" x1="79.702" x2="75.99199999999999" y1="61.69" y2="66.321"/>
            </g>
                  
            <line class="bond" id="mol1bnd10" x1="71.695" x2="78.299" y1="69.734" y2="83.45"/>
                  
            <line class="bond" id="mol1bnd11" x1="78.299" x2="73.482" y1="83.45" y2="93.455"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="56.862" x2="68.391" y1="100.621" y2="97.936"/>
                        
                <line x1="57.464" x2="67.838" y1="97.977" y2="95.561"/>
                      
                <line class="hi" stroke="#3050F8" x1="68.391" x2="62.62650000000001" y1="97.936" y2="99.27850000000001"/>
                <line class="hi" stroke="#3050F8" x1="67.838" x2="62.650999999999996" y1="95.561" y2="96.769"/>
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="56.862" x2="44.975" y1="100.621" y2="91.07"/>
                  
            <g class="bond" id="mol1bnd14">
                        
                <line x1="44.975" x2="44.975" y1="91.07" y2="75.83"/>
                        
                <line x1="42.536" x2="42.536" y1="89.662" y2="77.238"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd15" x1="53.83" x2="44.975" y1="68.716" y2="75.83"/>
                  
            <line class="bond" id="mol1bnd16" x1="44.975" x2="31.767" y1="75.83" y2="68.21"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="31.767" x2="18.559" y1="68.21" y2="75.83"/>
                        
                <line x1="31.767" x2="20.997" y1="71.025" y2="77.238"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="18.559" x2="18.559" y1="75.83" y2="91.07"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="18.559" x2="31.767" y1="91.07" y2="98.69"/>
                        
                <line x1="20.997" x2="31.767" y1="89.662" y2="95.875"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="44.975" x2="31.767" y1="91.07" y2="98.69"/>
                  
            <line class="bond" id="mol1bnd21" x1="18.559" x2="6.875" y1="91.07" y2="97.818"/>
                  
            <line class="bond" id="mol1bnd22" x1="56.862" x2="53.476" y1="100.621" y2="115.48"/>
                  
            <g class="bond" id="mol1bnd23">
                        
                <line x1="53.476" x2="38.997" y1="115.48" y2="119.974"/>
                        
                <line x1="52.85" x2="41.06" y1="118.227" y2="121.887"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd24" x1="38.997" x2="35.587" y1="119.974" y2="134.827"/>
                  
            <g class="bond" id="mol1bnd25">
                        
                <line x1="35.587" x2="46.656" y1="134.827" y2="145.187"/>
                        
                <line x1="38.277" x2="47.291" y1="134.005" y2="142.441"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd26" x1="46.656" x2="61.234" y1="145.187" y2="140.716"/>
                  
            <g class="bond" id="mol1bnd27">
                        
                <line x1="61.234" x2="64.644" y1="140.716" y2="125.862"/>
                        
                <line x1="59.172" x2="61.952" y1="138.797" y2="126.689"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd28" x1="53.476" x2="64.644" y1="115.48" y2="125.862"/>
                  
            <line class="bond" id="mol1bnd29" x1="64.644" x2="76.507" y1="125.862" y2="122.217"/>
                  
            <path class="atom" d="M63.207 28.649h-.72l-2.619 -4.066h-.03q.012 .239 .03 .596q.023 .357 .023 .732v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.005 -.107 -.017 -.327q-.012 -.221 -.024 -.477q-.006 -.261 -.006 -.482v-2.768h.577v4.899z" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M58.802 68.729h-.72l-2.619 -4.066h-.03q.012 .239 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm8" stroke="none"/>
                  
            <path class="atom" d="M83.483 57.837q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM79.62 57.837q-.0 .923 .387 1.459q.392 .53 1.22 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.928 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.226 .524q-.393 .524 -.393 1.452z" fill="#FF0D0D" id="mol1atm10" stroke="none"/>
                  
            <path class="atom" d="M73.636 99.616h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" id="mol1atm12" stroke="none"/>
                  
            <path class="atom" d="M2.906 96.877q-.786 -.0 -1.239 .529q-.452 .524 -.452 1.447q-.0 .911 .417 1.447q.422 .529 1.268 .529q.321 .0 .607 -.053q.292 -.06 .565 -.143v.536q-.273 .101 -.565 .149q-.292 .053 -.697 .053q-.744 .0 -1.25 -.309q-.5 -.31 -.75 -.876q-.25 -.571 -.25 -1.339q.0 -.744 .268 -1.31q.274 -.565 .804 -.881q.529 -.321 1.279 -.321q.78 -.0 1.352 .286l-.244 .523q-.226 -.101 -.506 -.184q-.274 -.083 -.607 -.083zM5.662 101.3h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm20" stroke="none"/>
                  
            <path class="atom" d="M78.459 123.836h-.613v-4.899h2.732v.541h-2.119v1.739h1.994v.542h-1.994v2.077z" fill="#90E050" id="mol1atm27" stroke="none"/>
                
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="64.234" x2="68.338" y1="23.448" y2="19.643"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="57.988" x2="52.3465" y1="25.187" y2="23.4445"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="62.136" x2="63.394000000000005" y1="30.015" y2="35.537"/>
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="55.993" x2="54.7345" y1="62.465" y2="56.9425"/>
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="60.166" x2="65.9305" y1="67.049" y2="68.39150000000001"/>
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="73.482" x2="75.8905" y1="93.455" y2="88.4525"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="53.83" x2="49.4025" y1="68.716" y2="72.273"/>
            <line class="hi" id="mol1bnd21" stroke="#1FF01F" x1="6.875" x2="12.717" y1="97.818" y2="94.44399999999999"/>
            <line class="hi" id="mol1bnd29" stroke="#90E050" x1="76.507" x2="70.5755" y1="122.217" y2="124.0395"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Anti-Anxiety Agents, Benzodiazepine; GABA Modulators; Sedatives, Nonbarbiturate","Title":"Flurazepam","UNII":"IHP475989U","Wikidata":"Q418998","XLogP":3}